Form DEFA14A Lakewood-Amedex Biothera

Mon, 10 Aug 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260810/26899145.html

Form DEF 14A Lakewood-Amedex Biothera For: Sep 22

Mon, 10 Aug 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260810/26899134.html

Form SCHEDULE 13G Lakewood-Amedex Biothera Filed by: Lindesfarne LLC

Thu, 06 Aug 2026 14:19:00 -0400

si-local-file:///var/storage/secattach/20260806/26882632.html

Form PRE 14A Lakewood-Amedex Biothera For: Jul 30

Thu, 30 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260730/26844247.html

Lakewood-Amedex shares resistance data for antibiotic candidate Nu-3

Wed, 22 Jul 2026 08:03:43 -0400

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) announced resistance data for its drug candidate Nu-3, a Phase 2-ready compound targeting infected diabetic foot ulcers (iDFU), according to a company press release.

The announcement follows the 27th Public Meeting of the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB), held on June 16, 2026, which focused on the next five-year National Action Plan on Combating Antibiotic-Resistant Bacteria.

Nu-3 is described by the company as working through a physical mechanism that disrupts bacterial membranes. In laboratory testing, Nu-3 did not induce resistance in a serial passage experiment. The compound also demonstrated in vitro activity against

Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria

Wed, 22 Jul 2026 08:02:00 -0400

Nu-3, a Phase 2-ready candidate targeting the treatment of infected diabetic foot ulcers (iDFU), targets disruption of bacterial membranes through a unique, physical mechanism of action and has demonstrated a high barrier to resistance.

SARASOTA, Fla., July 22, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin^® class, today announced resistance data for Nu-3 in alignment with the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB).

Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria

Wed, 22 Jul 2026 08:02:00 -0400

Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria

Wed, 22 Jul 2026 08:02:00 -0400

Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria

Wed, 22 Jul 2026 08:02:00 -0400

Form 8-K Lakewood-Amedex Biothera For: Jul 15

Wed, 15 Jul 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260715/26774344.html

Lakewood-Amedex reports preclinical safety data for Nu-3 gel trial

Wed, 15 Jul 2026 08:02:15 -0400

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) announced preclinical safety data for Nu-3, a gel formulation targeting the topical treatment of infected diabetic foot ulcers, as the company prepares for an upcoming Phase 2a clinical trial.

According to the company's press release, Nu-3 was well tolerated in an FDA-required safety study at dose levels substantially higher than those planned for the Phase 2a trial. Systemic exposure was reported as very low, suggesting a limited potential for systemic side effects.

The safety study also showed that Nu-3 did not inhibit wound healing. Based on the combined results of laboratory antimicrobial activity, animal model data, and

Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel

Wed, 15 Jul 2026 08:02:00 -0400

Nu-3 is a gel formulation of a Bisphosphocin® compound targeting the topical treatment of infected diabetic foot ulcers with low likelihood of producing systemic side effects.

SARASOTA, Fla., July 15, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin^® class, announced robust preclinical safety data that establishes a strong foundation for clinical dose selection in its upcoming Phase 2a clinical trial.

Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel

Wed, 15 Jul 2026 08:02:00 -0400

Nu-3 is a gel formulation of a Bisphosphocin® compound targeting the topical treatment of infected diabetic foot ulcers with low likelihood of producing systemic side effects.

Lakewood-Amedex backs PASTEUR Act, plans Phase 2 trial for Nu-3

Tue, 07 Jul 2026 08:03:11 -0400

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) announced its support for the reintroduction of the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act, legislation aimed at encouraging the development of new therapies to address antimicrobial resistance (AMR).

The clinical-stage biotechnology company said it is preparing to enter Phase 2 clinical development with its lead product candidate, Nu-3, as a topical therapy for infected diabetic foot ulcers (iDFU). The company described iDFUs as a condition affecting millions of patients worldwide and frequently leading to hospitalization or amputation when infections are not controlled at an early stage.

Nu-3 is part of Lakewood-Amedex's proprietary Bisphosphocin®

Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance

Tue, 07 Jul 2026 08:02:00 -0400

Company highlights its differentiated Bisphosphocin^® platform and lead clinical candidate Nu-3 as innovative approaches to addressing microbial infections and the risk of resistance development

SARASOTA, Fla., July 7, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin^® class, announced its support for the reintroduction of the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act, legislation designed to encourage the development of novel therapies to address the

Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance

Tue, 07 Jul 2026 08:02:00 -0400

Company highlights its differentiated Bisphosphocin^® platform and lead clinical candidate Nu-3 as innovative approaches to addressing microbial infections and the risk of resistance development

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing

Fri, 26 Jun 2026 08:35:00 -0400

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24^th & 25^th Life Sciences Virtual Investor Forum are now available for on-demand viewing.

REGISTER AND VIEW PRESENTATIONS HERE

Select companies are accepting 1x1 management meeting requests through June 19^th. Please Schedule 1x1 Meetings here.